Condition: MDS/MPN · Sponsor: Michael Savona
ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response. ABNL MARRO 001 (AM-001) is an Open label, phase 1/2 study within the framework of the ABNL-MARRO that will test novel treatment combinations in MDS/MPN. Each Arm of AM-001 will test an active myeloid target compound in combination with ASTX727, an oral drug combining fixed doses of the DNA methyltransferase inhibitor (DNMTi) decitabine and the cytidine deaminase inhibitor E7727, also known as cedazuridine in a single tablet.
This description comes directly from the study's public registry record.
Theradex Oncology US Inquiry · 609.799.7580 · info@theradex.com
Theradex Oncology EU Inquiry · +44 (0)1293 510 319 · enquiry@theradex.co.uk
Always discuss trial participation with your own doctor first.
| Moffitt Cancer Center | Tampa, Florida, United States | Suspended |
| University of Rochester Wilmot Cancer Institute | Rochester, New York, United States | Recruiting |
| Oregon Health Sciences University | Portland, Oregon, United States | Recruiting |
| Vanderbilt-Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04061421